UNIVERSIDAD DE ANTIOQUIA

Unravel Biosciences Advances RVL-001 to Clinical Trials for Rett and Pitt Hopkins Syndromes in Colombia

23 days ago

• Unravel Biosciences has submitted clinical study applications for RVL-001 trials in Rett syndrome and Pitt Hopkins syndrome to Colombia's INVIMA under a fast-track program for rare diseases. • The placebo-controlled "n-of-1" trials will enroll 15 patients with Rett syndrome and 5 with Pitt Hopkins syndrome at Universidad de Antioquia's PECET in Medellin, with anticipated study initiation in early summer. • RVL-001 was identified through Unravel's proprietary BioNAV™ drug discovery platform as a promising therapeutic for these rare neurogenetic disorders that currently have limited or no treatment options.